According to Future Market Insights (FMI) analysis in a recent market survey, the global axillary hyperhidrosis treatment market was valued at US$ 1.6 Billion in 2022 and is expected to reach US$ 3.3 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.6 Billion |
| Market Value 2023 | US$ 1.8 Billion |
| Market Value 2033 | US$ 3.3 Billion |
| CAGR 2023 to 2033 | 6.7% |
| Share of Top 5 Countries | 53.6% |
| Key Players | The key players in the axillary hyperhidrosis treatment market are Allergan plc. (AbbVie), Journey Medical Corporation (Dermira, Inc.), Riemann A/S (Orkla), SweatBlock, Certain Dri, miraDry, Inc. (Sientra), STRATUS PHARMACEUTICALS INC, Duradry, Pers?n & Covey, GlaxoSmithKline Plc., Carpe, SweatStop® International, CORAD Healthcare, ZeroSweat |
Anti-sweat injections are nowadays considered to be the best option for treating axillary hyperhidrosis as these don't require any incisions.
Doctors are now employing Botox as a successful alternative to treat hyperhidrosis for individuals who want long-lasting results or for whom conventional antiperspirants are ineffective. The FDA has licensed Botox for the treatment of axillary hyperhidrosis in individuals who frequently perspire.
Medicated wipes and gels are also effective substitutes. These products contain active ingredients such as aluminum chloride or aluminum zirconium tetrachlorohydrex glycine, which work by blocking sweat ducts and reducing the amount of sweat produced. One advantage of medicated wipes and gels is that they are non-invasive and do not require any medical procedures. However, another advantage is that they can be more effective than other traditional treatment options. Medicated wipes and gels contain higher concentrations of active ingredients, which can provide longer-lasting and more reliable results.
Overall, the increasing use of medicated wipes and gels in the treatment of hyperhidrosis is likely due to their convenience, efficacy, and safety, which will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the axillary hyperhidrosis treatment market grew at a CAGR of 7.2% between 2017 to 2022. Axillary hyperhidrosis treatment market contributes 5.1% revenue share to the global dermatology therapeutics market in 2022.
The increasing availability of over-the-counter and labelled medications for the treatment of axillary hyperhidrosis will further result in higher uptake of various treatment options such as antiperspirants, thus leading to market expansion. Because of their easy availability and affordability, antiperspirants are typically the first form of treatment recommended by a dermatologist worldwide for axillary hyperhidrosis.
With the advancement of therapies such as iontophoresis and antiperspirants, axillary hyperhidrosis can now be treated more successfully than in the past. For the treatment of hyperhidrosis, more recent treatment options like miraDry, Botox injections, and lasers have significantly increased patient satisfaction and emerged as effective treatment options for axillary hyperhidrosis, which has led to the higher adoption of such products and therapies in the global market.
Prevalence of diabetes and obesity increases the chances of secondary hyperhidrosis in patients. Diabetes can lead to nerve damage that can affect the body's ability to regulate sweating. Menopause can also lead to hormonal changes that affect sweating. Obesity can lead to excessive sweating due to increased body mass and associated heat production.
Considering this, FMI expects the global axillary hyperhidrosis treatment market to grow at a CAGR of 6.7% through the forecasted years.
There is a lack of awareness regarding axillary hyperhidrosis, which is excessive sweating in the armpits Many people who suffer from this condition may not realize that it is a medical condition that can be treated. They may be embarrassed to talk about it, or believe it is just a normal reaction of their body to heat or stress.
As a result, many people with axillary hyperhidrosis do not seek treatment, which can lead to social isolation, anxiety, and low self-esteem. Secondly, healthcare providers may not recognize the condition or may not know how to effectively treat it.
Healthcare professionals are also experimenting with various combination therapies/treatments and seeing positive results in their patients, especially with oral medications. Oral medications are generally not a viable, long-term, sole option due to their side effects. Instead, other treatments can be combined with them to achieve the best results, and new formulations can make them easier for more patients.
Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.
Principal Consultant
Many people suffering from axillary hyperhidrosis are not aware that there are treatments available for their condition. This lack of awareness could result in fewer patients seeking treatment, thereby limiting the growth of the market.
Some of the treatments for axillary hyperhidrosis, such as antiperspirants and botox injections, may have side effects that could discourage patients to seek treatment and pursue alternative therapies, such as herbal remedies or acupuncture, instead of conventional medical treatments, which could limit the growth of the market for conventional treatments.
The potential side effects of antiperspirants and Botox injections may deter some patients from using these treatments, and could limit their uptake.
These factors are expected to hamper revenue growth of the axillary hyperhidrosis treatment market over the forecast period.
The USA axillary hyperhidrosis treatment market is expected to register a CAGR of 5.0% during the forecast period.
The high prevalence of primary and secondary hyperhidrosis in the United States will accelerate the acceptance of various treatment alternatives.
Due to the high prevalence, more treatments, including over-the-counter products such as antiperspirants and wipes, will experience a high adoption rate among patients. The demand for axillary hyperhidrosis treatment will increase due to high prevalence, which will drive the expansion of the market.
Germany dominated the European market for axillary hyperhidrosis treatment and accounted for around 22.2% of the market share in 2022.
Over the years, miraDry has completely overshadowed these invasive procedures owing to its non-invasive nature while providing the treatment.
Since 2014, Munich’s German Hyperhidrosis Center (DHHZ) has been offering this treatment and is the first miraDry treatment facility certified in Germany and Europe. Since 2015, miraDry has also been further developed and improved for the treatment of excessive sweating in the groin, buttocks, and trunk.
The safe and successful use of miraDry treatments in Germany will influence other European countries to also opt for this treatment method, ultimately expanding the overall market.
China is projected to be the most attractive market in the axillary hyperhidrosis treatment, and is expected to grow over a significant CAGR of 8.3%.
The axillary hyperhidrosis treatment market in China is expected to grow significantly in the coming years due to several factors.
One of the main factors driving the growth of the axillary hyperhidrosis treatment market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek treatment, which is leading to increased demand for treatments for axillary hyperhidrosis.
Another factor contributing to the growth of the axillary hyperhidrosis treatment market in China is the increasing availability of advanced medical technologies and treatments. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years. This has allowed for the introduction of advanced treatments such as botox injections and surgery, which were not widely available in the past.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The drug therapy segment held the major chunk of about 62.7% in global market by the end of 2022.
Drug therapy is a non-invasive treatment option that does not require any surgical procedures or injections. This makes it a less risky and more comfortable option for patients who may be apprehensive about more invasive treatments.
Certain medications, such as antiperspirants and oral anticholinergic drugs, have been shown to be effective in reducing excessive sweating in patients with axillary hyperhidrosis. These medications can be effective in reducing sweat production with minimal side effects. This makes it a safer and more tolerable option for patients who may be concerned about potential side effects.
Overall, drug therapy is a widely adopted treatment option for axillary hyperhidrosis due to its non-invasive nature, efficacy, accessibility, cost-effectiveness, and minimal side effects.
The retail pharmacy segment accounted for revenue share of 34.2% in the global market at the end of 2022.
Retail pharmacies offer convenient access to treatment options, with many providing over-the-counter and prescription medications for a range of conditions, including axillary hyperhidrosis. Patients can typically purchase these treatments without an appointment, making it more convenient for them to manage their condition.
Overall, retail pharmacy offers a convenient and accessible distribution channel for axillary hyperhidrosis treating products, making it the largest channel for these treatments.
Key players in the market are focused on increase their product portfolio to strengthen their position in the axillary hyperhidrosis treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition & distribution agreement of other companies to expand their business.
For instance
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the axillary hyperhidrosis treatment market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, United kingdom, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Treatment, Distribution Channel, and Region |
| Key Companies Profiled | Allergan plc. (AbbVie); Journey Medical Corporation (Dermira, Inc.); Riemann A/S (Orkla); SweatBlock; Certain Dri; miraDry, Inc. (Sientra); STRATUS PHARMACEUTICALS INC; Duradry; Persn & Covey; GlaxoSmithKline Plc.; Carpe; SweatStop® International; CORAD Healthcare; ZeroSweat |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global market might create a revenue of around USD 1.8 billion in 2023.
Adoption of such treatments in the United States may increase at 5% CAGR through 2033.
Germany dominates the region and accounted for 22.2% market share in 2022.
Drug therapy segment held 62.7% of the global market in 2022.
Retail pharmacies achieved 34.2% of the global sales in 2022.
1. Executive Summary | Axillary Hyperhidrosis Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology
4.2. Patent Analysis
4.3. Pipeline Assessment
4.4. Value Chain Analysis
4.5. Regulatory Scenario
4.6. PESTLE Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Dermatology Therapeutics Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Prevalence of Axillary Hyperhidrosis
5.2.2. Treatment Seeking Rate (%)
5.2.3. Adoption of Various Treatment Modalities
5.2.4. Greater Demand for Non-Invasive Procedures
5.2.5. Increasing Initiatives by Manufacturers to Educate the General Population
5.2.6. Products in Pipeline
5.2.7. Availability of Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Treatment
6.1.2. By Distribution Channel
6.1.3. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis 2017 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Treatment
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Treatment, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Treatment, 2023 to 2033
8.3.1. Drug Therapy
8.3.1.1. Antiperspirants (Both OTC & Rx)
8.3.1.1.1. Antiperspirants Spray
8.3.1.1.2. Antiperspirants Roll-On
8.3.1.1.3. Antiperspirants Wipes
8.3.1.1.4. Antiperspirants Lotion & Gel
8.3.1.2. Antihypertensive Drugs
8.3.1.3. Anticholinergic Agents
8.3.1.4. Alpha-Adrenergic Agonists
8.3.2. Botulinum Toxins
8.3.3. Medicated Wipes
8.3.4. Microwave Therapy
8.4. Market Attractiveness Analysis By Treatment
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction
9.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
9.3.1. Hospitals
9.3.2. General Physician’s Clinics
9.3.3. Retail Pharmacy Chains
9.3.4. Drug Stores
9.3.4.1. Online Sales
9.3.4.2. Manufacturer websites
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Value (US$ Million) Analysis By Region, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
11.3.1. By Country
11.3.1.1. USA
11.3.1.2. Canada
11.3.2. By Treatment
11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Treatment
11.4.3. By Distribution Channel
11.5. Market Trends
11.6. Key Market Participants - Intensity Mapping
11.7. Drivers and Restraints - Impact Analysis
11.8. Country Level Analysis & Forecast
11.8.1. USA Market
11.8.1.1. Introduction
11.8.1.2. Market Analysis and Forecast by Market Taxonomy
11.8.1.2.1. By Treatment
11.8.1.2.2. By Distribution Channel
11.8.2. Canada Market
11.8.3. Introduction
11.8.4. Market Analysis and Forecast by Market Taxonomy
11.8.4.1.1. By Treatment
11.8.4.1.2. By Distribution Channel
12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Treatment
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Treatment
12.4.3. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. Brazil Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Treatment
12.8.1.2.2. By Distribution Channel
12.8.2. Mexico Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Treatment
12.8.2.2.2. By Distribution Channel
12.8.3. Argentina Market
12.8.4. Introduction
12.8.5. Market Analysis and Forecast by Market Taxonomy
12.8.5.1.1. By Treatment
12.8.5.1.2. By Distribution Channel
13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. United kingdom
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Nordic Countries
13.3.1.9. Rest of Europe
13.3.2. By Treatment
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Treatment
13.4.3. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Germany Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Treatment
13.8.1.2.2. By Distribution Channel
13.8.2. Italy Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Treatment
13.8.2.2.2. By Distribution Channel
13.8.3. France Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Treatment
13.8.3.2.2. By Distribution Channel
13.8.4. United kingdom Market
13.8.4.1. Introduction
13.8.4.2. Market Analysis and Forecast by Market Taxonomy
13.8.4.2.1. By Treatment
13.8.4.2.2. By Distribution Channel
13.8.5. Spain Market
13.8.5.1. Introduction
13.8.5.2. Market Analysis and Forecast by Market Taxonomy
13.8.5.2.1. By Treatment
13.8.5.2.2. By Distribution Channel
13.8.6. BENELUX Market
13.8.6.1. Introduction
13.8.6.2. Market Analysis and Forecast by Market Taxonomy
13.8.6.2.1. By Treatment
13.8.6.2.2. By Distribution Channel
13.8.7. Russia Market
13.8.7.1. Introduction
13.8.7.2. Market Analysis and Forecast by Market Taxonomy
13.8.7.2.1. By Treatment
13.8.7.2.2. By Distribution Channel
13.8.8. Nordic Countries Market
13.8.8.1. Introduction
13.8.8.2. Market Analysis and Forecast by Market Taxonomy
13.8.8.2.1. By Treatment
13.8.8.2.2. By Distribution Channel
14. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Treatment
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Treatment
14.4.3. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. China Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Treatment
14.8.1.2.2. By Distribution Channel
14.8.2. Japan Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Treatment
14.8.2.2.2. By Distribution Channel
14.8.3. South Korea Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Treatment
14.8.3.2.2. By Distribution Channel
15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Treatment
15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Treatment
15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. India Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Treatment
15.8.1.2.2. By Distribution Channel
15.8.2. Indonesia Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Treatment
15.8.2.2.2. By Distribution Channel
15.8.3. Malaysia Treatment Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Treatment
15.8.3.2.2. By Distribution Channel
15.8.4. Thailand Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Treatment
15.8.4.2.2. By Distribution Channel
16. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Treatment
16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Treatment
16.4.3. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Australia Treatment Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Treatment
16.8.1.2.2. By Distribution Channel
16.8.2. New Zealand Treatment Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Treatment
16.8.2.2.2. By Distribution Channel
17. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Value (US$ Million) Analysis, By Market Taxonomy 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast, By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Türkiye
17.3.1.3. South Africa
17.3.1.4. North Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Treatment
17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Treatment
17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. GCC Countries Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Treatment
17.8.1.2.2. By Distribution Channel
17.8.2. Türkiye Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Treatment
17.8.2.2.2. By Distribution Channel
17.8.3. South Africa Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Treatment
17.8.3.2.2. By Distribution Channel
17.8.4. North Africa Market
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Treatment
17.8.4.2.2. By Distribution Channel
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis (%) of Top Players
18.3. Market Presence Analysis
18.3.1. Regional Footprint of Players
18.3.2. Channel Foot Print by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Promotional and Branding Strategies by Manufacturers
19.4. Competition Deep Dive
19.4.1. Allergan plc. (AbbVie)
19.4.1.1. Overview
19.4.1.2. Treatment Portfolio
19.4.1.3. Sales Footprint
19.4.1.4. Key Financials
19.4.1.5. SWOT Analysis
19.4.1.6. Strategy Overview
19.4.2. Journey Medical Corporation (Dermira, Inc.)
19.4.2.1. Overview
19.4.2.2. Treatment Portfolio
19.4.2.3. Sales Footprint
19.4.2.4. Key Financials
19.4.2.5. SWOT Analysis
19.4.2.6. Strategy Overview
19.4.3. Riemann A/S (Orkla)
19.4.3.1. Overview
19.4.3.2. Treatment Portfolio
19.4.3.3. Sales Footprint
19.4.3.4. Key Financials
19.4.3.5. SWOT Analysis
19.4.3.6. Strategy Overview
19.4.4. SweatBlock
19.4.4.1. Overview
19.4.4.2. Treatment Portfolio
19.4.4.3. Sales Footprint
19.4.4.4. Key Financials
19.4.4.5. SWOT Analysis
19.4.4.6. Strategy Overview
19.4.5. Certain Dri
19.4.5.1. Overview
19.4.5.2. Treatment Portfolio
19.4.5.3. Sales Footprint
19.4.5.4. Key Financials
19.4.5.5. SWOT Analysis
19.4.5.6. Strategy Overview
19.4.6. miraDry, Inc. (Sientra)
19.4.6.1. Overview
19.4.6.2. Treatment Portfolio
19.4.6.3. Sales Footprint
19.4.6.4. Key Financials
19.4.6.5. SWOT Analysis
19.4.6.6. Strategy Overview
19.4.7. STRATUS PHARMACEUTICALS INC
19.4.7.1. Overview
19.4.7.2. Treatment Portfolio
19.4.7.3. Sales Footprint
19.4.7.4. Key Financials
19.4.7.5. SWOT Analysis
19.4.7.6. Strategy Overview
19.4.8. Duradry
19.4.8.1. Overview
19.4.8.2. Treatment Portfolio
19.4.8.3. Sales Footprint
19.4.8.4. Key Financials
19.4.8.5. SWOT Analysis
19.4.8.6. Strategy Overview
19.4.9. Persōn & Covey
19.4.9.1. Overview
19.4.9.2. Treatment Portfolio
19.4.9.3. Sales Footprint
19.4.9.4. Key Financials
19.4.9.5. SWOT Analysis
19.4.9.6. Strategy Overview
19.4.10. GlaxoSmithKline Plc.
19.4.10.1. Overview
19.4.10.2. Treatment Portfolio
19.4.10.3. Sales Footprint
19.4.10.4. Key Financials
19.4.10.5. SWOT Analysis
19.4.10.6. Strategy Overview
19.4.11. Carpe
19.4.11.1. Overview
19.4.11.2. Treatment Portfolio
19.4.11.3. Sales Footprint
19.4.11.4. Key Financials
19.4.11.5. SWOT Analysis
19.4.11.6. Strategy Overview
19.4.12. SweatStop® International
19.4.12.1. Overview
19.4.12.2. Treatment Portfolio
19.4.12.3. Sales Footprint
19.4.12.4. Key Financials
19.4.12.5. SWOT Analysis
19.4.12.6. Strategy Overview
19.4.13. CORAD Healthcare
19.4.13.1. Overview
19.4.13.2. Treatment Portfolio
19.4.13.3. Sales Footprint
19.4.13.4. Key Financials
19.4.13.5. SWOT Analysis
19.4.13.6. Strategy Overview
19.4.14. ZeroSweat
19.4.14.1. Overview
19.4.14.2. Treatment Portfolio
19.4.14.3. Sales Footprint
19.4.14.4. Key Financials
19.4.14.5. SWOT Analysis
19.4.14.6. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Axillary Hyperhidrosis Treatment Market
